Clinical trial
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of…
NCT00424671 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00424671 |
|---|---|
| Title | Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine |
| Official title | An Open-Label Study in Healthy Subjects and in Subjects With Stable Impaired Hepatic Function to Assess the Effect of Moderate Hepatic Impairment on Licarbazepine Pharmacokinetics and Metabolism After a Single Dose of 1000 mg Licarbazepine IR Tablets |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Licarbazepine |
| Enrollment | 16 |
| Start date | Nov 1, 2006 |
| First posted | Jan 19, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: